NYSE:NVO

Novo-Nordisk (NVO-N)

55.23
-0.91 (1.62%)
as of Sep 5, 2025, 8:00:00 pm Market Open.
259 watching
0

Related posts

Nervous markets await Nvidia
Investor Insights
Apr 16, 2025, 12:00 am

This summary was created by AI, based on 40 opinions in the last 12 months.

Novo-Nordisk is facing challenges in the competitive landscape of obesity and diabetes drugs, particularly against Eli Lilly, which is gaining market share. Experts indicate that while NVO's stock has declined significantly, with a current valuation around 19x to 22x forward PE and expected growth rates of 14-25%, the company remains a leader in weight-loss treatments. The company benefits from strong brand recognition and ongoing demand for its obesity drugs like Ozempic and Wegovy. However, analysts express concerns about the heavy reliance on a few major drugs and the potential impact of increasing competition in the weight-loss sector. Overall, while there is a belief in long-term growth prospects due to rising obesity rates, current market conditions and short-term volatility present caution for investors considering new positions.

Consensus
Hold
Valuation
Fair Value

Most recent Opinions go here

Be up to date, don’t miss your chance.

WATCH

Falling rapidly after a great run. Price is below 200-day MA. Valuations look somewhat attractive, but sentiment remains pretty rough. 14x forward PE for 8-10% growth. Guided lower for the year. 

Great long-term catalysts, as Wegovy shows strength in treating obesity, diabetes, heart attacks, stroke, and liver disease. But it's all about patent cliffs, pricing risks, and competition.

DON'T BUY

There are worried about generic weight-loss drugs coming. Pharmaceuticals are like fads and fashions, hard to know where the market will be. He avoids pharma.

TOP PICK

It was the biggest European company last year. This and LLY are growing double digits and the market is growing double digits. Has owned NVO 9 years and trimmed it 7 times, and this is the first time he's bought more, on weakness. Obesity and diabetes are not going away. 

(Analysts’ price target is $64.51)
COMMENT
Shares are plunging 23% over falling US demand for its key drugs.

The key drug is its weight-loss one, a class of drugs he believes in and feels will be the biggest drug on the world ever, worth $120 billion in 2030. Huge growth. These drugs offer cardio benefits in addition to weight-loss. He prefers LLY.

BUY

He's owned this since 2015, trimming 7 times (that's just good risk management). Markets were pushed well ahead of themselves in 2024, and then we saw a big retraction. Fast money has come out of this name. Down ~60%, growing double digits, 16x forward PE (vs. LLY at 43x forward PE). LLY is really strong in the US, but not outside. 

At this valuation, a no-brainer. Again, you make $$ when you buy not when you sell. He's going to wait and see what happens with the CEO position.

BUY

Deal to get off injectables and over to tablets. Went up too far, too fast, now has fallen. LLY has 60% of revenues in US, NVO has 60% outside US. Concern is that LLY's product helps people lose more weight. But Type 2 diabetics are still growing worldwide, especially in China and India.

Trades ~16x PE, lowest it's been in almost 20 years. He's buying more. The value is there, and the company's not getting any credit for its weight-loss drug. Don't hold both LLY and NVO, as it's correlation risk.

PAST TOP PICK
(A Top Pick Apr 10/24, Down 51%)

Overvalued to start with, and expectations were high. Small miss on weight loss percentage led to huge drop in stock price. LLY is grabbing more market share. Worry that drugs in US will face tariffs. Buy here, do well in the long run.

BUY ON WEAKNESS

He prefers Eli Lilly, but shares of NVO have come down enough.

PAST TOP PICK
(A Top Pick Mar 06/24, Down 51%)

He's out. Valuation has now become fairly attractive at 16x forward PE for 14-15% growth. Below 200-week MA, troubling. Long term, a name to look at again once things turn around. Losing some market share to LLY.

DON'T BUY

Now a whole slew of competitors in the weight-loss space. He'd prefer a more diversified pharma company.

BUY ON WEAKNESS

Is -17% this year and -42% the past year. It went too far too fast. He's been buying more on the way down, because obesity won't change, so their weight-loss drug will keep selling. Tariffs: NVO has facilities in the US already. 60% of revenues are outside North America (vs. Eli Lilly's 60% within US). To extend patent protection, a pharma company just needs to change its formula every 3 years to extend the patent protection. There will be competition, but NVO has brand recognition and scale.

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

Its stock decline is not unique in this market: most growth companies have been hit very very hard, in one of the sharpest sell-offs we have seen in some time. NVO is 19X earnings now, with a 2.90% dividend. The balance sheet is fine and good growth is still expected over the next two years. We would be comfortable owning this and riding out the current market malaise, which will end one of these days (weeks, or months).
Unlock Premium - Try 5i Free

PAST TOP PICK
(A Top Pick Mar 26/24, Down 41%)

Sentiment's pretty rough on this name. Fairly cheap at 22x forward PE, 18% earnings growth. Regulatory scrutiny. Lost a bit of market share to LLY (which he still holds). Below 200-day MA, which is moving down. Growth of GLP-1 drugs is there, so he's keeping an eye on it for future.

DON'T BUY

So many companies now with competing weight-loss products. Riding the hype on this one drug, and he'd much prefer more diversification.

BUY

Has owned this a long time, but has trimmed recently. Unfortunately, diabetes is a growing business. Stocks have fallen recently, because supply couldn't meet demand, but the price is attractive and reasonable.

Showing 1 to 15 of 176 entries

Novo-Nordisk(NVO-N) Rating

Ranking : 5 out of 5

Star iconStar iconStar iconStar iconStar icon

Bullish - Buy Signals / Votes : 16

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 27

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 27 stock analysts published opinions about NVO-N. 16 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

27 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2025-09-05, Novo-Nordisk (NVO-N) stock closed at a price of $55.23.